
APGE Stock Forecast & Price Target
APGE Analyst Ratings
Bulls say
Apogee Therapeutics is poised for success with its differentiated pipeline of biologic therapies targeting well-established mechanisms of action, specifically in the inflammatory and immunology markets. The recent acquisition by AbbVie brings validation to the company's potential and helps to mitigate risks. The company's longer-acting dosing and potential for deeper and broader clinical benefits, along with potential catalysts in the near future, make for an exciting investment opportunity.
Bears say
Apogee Therapeutics is facing numerous challenges in commercializing their lead program zumilokibart, including potential safety issues and ABBV's decision to not include APG-279 in their sales estimates. This has led to a revision of the company's fair value estimate to $135/shr, a decrease from previous estimates. Additionally, the company faces challenges in terms of diverse hiring and sustainable practices, which could potentially impact their future growth and success.
This aggregate rating is based on analysts' research of Apogee Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
APGE Analyst Forecast & Price Prediction
Start investing in APGE
Order type
Buy in
Order amount
Est. shares
0 shares